FAKTOR-OPTIONSSCHEIN - INCYTE CO. | Real-time Boerse Frankfurt Warrants 05:01:32 2024-06-26 EDT | ||
| 10.4 EUR | -0.10% |
|
| Current month | -7.63% | ||
| 1 month | -8.12% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 10.4 | -0.10% |
| 24-06-25 | 10.41 | +0.97% |
| 24-06-24 | 10.31 | -1.06% |
| 24-06-21 | 10.42 | -0.48% |
| 24-06-20 | 10.47 | -1.87% |
Real-time Boerse Frankfurt Warrants
Last update June 26, 2024 at 05:01 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | 
Société Générale
|
| WKN | SD416W |
| ISIN | DE000SD416W8 |
| Date issued | 2021-03-29 |
| Strike | 79.94 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 8.49 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.07 € |
|---|---|
| Lowest since issue | 7.4 € |
| Spread | 0.15 € |
| Spread % | 1.42% |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
63.1
USD
Average target price
72.8
USD
Spread / Average Target
+15.37%
- Stock Market
- Certificates
- Certificat
